Teva receives FDA nod for QVAR

JERUSALEM — Teva Pharmaceutical on Friday announced that the Food and Drug Administration approved the use of QVAR (beclomethasone dipropionate HFA) with a dose counter for the treatment of asthma in patients 5 years of age and older.



The counter will help asthma patients and their caregivers keep track of the number of remaining doses in the canister. It will be commercially available later this year, according to the company.



“Inhaled corticosteroid treatments, like QVAR, should be taken daily by patients with mild-to-moderate persistent asthma to reduce inflammation in the airways and prevent asthma symptoms,” said Dr. Gene Colice, director of pulmonary, critical care and respiratory services at Washington Hospital Center in Washington, D.C. “By using QVAR with a dose counter, patients will be able to easily track their daily doses of medication and help ensure that they are taking QVAR as prescribed by their doctor.